Navigation Links
Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company's Growth and International Expansion Plan

PASADENA, Calif., Feb. 7, 2013 /PRNewswire/ --

Immunotech Laboratories, Inc. (PINKSHEETS : IMMB ) Immunotech Laboratories, Inc., today announced the appointment of Mr. Valentin Dimitrov to the company Board of Directors as Chief Financial Advisor effective immediately.

Mr. Dimitrov (48) has an impressive professional history in the International Pharmaceutical World along with an impressive background in the formation and management of International Corporations, including the founding member and supervisory Board Chairman of the International Orthodox Bank – (present "Investbank" JSC).

Immunotech Director Bo Linton , further commented Mr. Dimitrov has an extensive knowledge of the Immunotech "IPF" patented technology and has worked alongside the company for several years, assisting with International awareness and potential Clinical Trial progression for the company's Immunotherapy Treatments.

Immunotech President Harry Zhabilov commented, "We are very pleased to announce the appointment of Valentin to the Board of Directors and feel he will be a valuable member of our team, and significantly help accelerate the progression of the company towards FDA approval for the 'IPF' technology."

The appointment of Mr. Dimitrov to Immunotech's Board of Directors helps with the potential goal of upgrading the company to the NASDAQ exchange, where a minimum of 5 Board Members are required.About Valentin Lordanov DimitrovEDUCATION:Kliment Ohridski University

Master's degree - Social PedagogicsKiev State University, Ukraine

Bachelor of International Diplomatic RelationsSPECIALIZATIONS:1995:

University of National and World Economy – Sofia - Finances1999:

Chemical-technological University - Sofia - Organic chemistry LANGUAGES:English - Fluent , Russian - fluent , German – spokenPROFESSIONAL BACKGROUND:2007-Current: "Vital-Fe" LTD – Distribution of bio-technology and pharmaceutical products – Director2003-Present"Bulgarian Association of Chemical and Fertilizer Industry" – Chairman2002-2003"Chimco Vienna" GmbH – Distributor of chemical and pharmaceutical products – Director1999-2002"CHIMCO" JSC, Vratza - Chemical production plant - Chairman of the Board of Directors1992-1998"Prima Gas" JSC – supply of natural gas – Director1995-1996"International Orthodox Bank" – (present "Investbank" JSC), Founder and member of the Supervisory Board1994-1995"Private Agricultural and Investment Bank" – Member of the Supervisory Board1990-1991 "Pharmachem" JSC – pharmaceutical and chemical industry – Director of DepartmentSafe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact:

Investor Relations:
The Nabors Group: 713-875-9200

CSNNewswire – Be Seen

SOURCE Immunotech Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Oz, Host Of The Dr. Oz Show, and Harry Zhabilov Of Immunotech Laboratories Discuss Immunotherapy Treatments For Cancer, HIV/AIDS
2. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
3. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
4. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
5. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
6. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
7. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
8. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
9. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
10. IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
11. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):